{
  "attach_pages": "3",
  "attach_size": "668",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP202009011405194909_1.pdf?1598978134000.pdf",
  "company_code": "80000031",
  "eitime": "2020-09-01 16:35:34",
  "extend": {},
  "info_code": "AP202009011405194909",
  "language": "0",
  "notice_date": "2020-09-01 00:00:00",
  "notice_title": "业绩受疫情影响明显，打造仿制药产品集群",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "A",
  "researcher": "朱国广",
  "security": [
    {
      "market_uni": "0",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "科伦药业",
      "short_name_ch": "科伦药业",
      "short_name_cht": "科倫藥業",
      "short_name_en": "KELUN PHARMA",
      "stock": "002422"
    }
  ],
  "short_name": "科伦药业",
  "source_sample_name": "东吴证券",
  "star": "3"
}